Animal healthcare is moving beyond treating disease only after symptoms appear. Long-acting biologics are targeting disease mechanisms, diagnostic testing is moving closer to clinics and homes, and livestock platforms are combining sensors, genomics, and breeding data.
However, technology development is moving faster than clinical adoption in some areas. Librela’s declining US sales challenge the wider biologics growth narrative. No lifespan-extension drug has been approved for any species. Livestock-sensor platforms remain fragmented, while antibiotic-reduction feed additives have not demonstrated consistent performance comparable to antibiotics.
62%
of dog skin and subcutaneous masses remained undiagnosed
$100 Million
raised by Loyal in its February 2026 Series C
1,000+ Farms
already use Halter’s smart-collar technology.
What’s Inside the Report?
Antibiotic-Reduction Feed Additives :Understand how regulation is driving probiotics, phytogenics, microbial solutions, and bacteriophage-based alternatives. The report maps activity from Novozymes, Evonik, ADM, dsm-firmenich, Truevet, Naturesactiv, BioFeed Technology, and Proteon. It also assesses a central unresolved question: whether these alternatives can consistently match antibiotic performance across species, production systems, and geographies. can consistently match antibiotic performance across species, production systems, and geographies.
Biologic Disease-Modifiers for Chronic Pet Conditions :Examine how monoclonal antibodies, gene therapies, and stem-cell platforms are moving beyond symptom management. The report covers long-acting anti-NGF therapies, Elanco’s biologics pipeline, and emerging platforms from Gallant, VetStem, Rejuvenate Bio, Animerra, and Eyam Health.It also examines a significant counter-signal: Librela’s US sales declined 16% year over year in 2025 and 32% in Q4, showing that commercial performance has not matched the wider approval and pipeline momentum.
Decentralized Veterinary Diagnostics :Explore how point-of-care hardware, at-home PCR panels, non-invasive testing, and AI-assisted cancer screening are moving diagnostic capabilities beyond centralized laboratories. .Despite these technologies being available, 62% of dog skin and subcutaneous masses remained undiagnosed in the cited survey. The report examines clinical adoption and workflow integration as the primary barriers.
Companion-Animal Longevity Therapeutics :Assess Loyal’s progress through the FDA conditional-approval pathway, rapamycin-based approaches, the NIH-funded TRIAD trial, and biological-age prediction tools from Nestlé Purina and Hill’s. The report distinguishes longevity-related activity from an approved lifespan-extension claim, which does not yet exist for any species.
Precision Livestock Management : Review commercially deployed sensing, feed-monitoring, genomics, and breeding platforms from companies including Halter, BinSentry, CowManager, Zoetis, Vytelle, Genus, and Nbryo. The report also examines the lack of established interoperability standards, limited on-farm ROI evidence, and fragmentation across competing sensor platforms.
- Commercial, regulatory, scientific, funding, and patent signals across five key animal-health trends
- Strategic R&D framework covering when to build, partner, license, invest, scout, or watch
- Company positioning, near-term milestones, and validation gaps across biologics, diagnostics, longevity, livestock technologies, and feed additives
